Histamine
Ceplene (histamine) is a small molecule pharmaceutical. Histamine was first approved as Histamine phosphate on 1982-01-01. It is used to treat allergic rhinitis seasonal and urticaria in the USA. It has been approved in Europe to treat myeloid leukemia acute. It is known to target carbonic anhydrase 7, histamine H2 receptor, histamine H1 receptor, histamine H4 receptor, carbonic anhydrase 5A, mitochondrial, histamine H3 receptor, and carbonic anhydrase 1.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| 2nd chance mobility pain relief | C200263 | 2024-01-08 |
| activon ultra strength arthritis | OTC monograph not final | 2015-04-22 |
| alo therapeutic massage | C200263 | 2023-11-10 |
| alo therapeutic massage pain relieving | C200263 | 2023-11-10 |
| amino active topical analgesic cream | C200263 | 2023-11-11 |
| arthritis pain relief | C200263 | 2024-12-11 |
| arthritis pain relief cream | OTC monograph not final | 2019-12-09 |
| australian dream back pain | C200263 | 2024-01-18 |
| back pain cream | OTC monograph not final | 2019-12-09 |
| bakers best arthritis pain relief | C200263 | 2023-11-11 |
Show 17 more
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| allergic rhinitis seasonal | EFO_0003956 | D006255 | J30 |
| urticaria | EFO_0005531 | D014581 | L50 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L03: Immunostimulants
— L03A: Immunostimulants
— L03AX: Other immunostimulants in atc
— L03AX14: Histamine dihydrochloride
V: Various drug classes in atc
— V04: Diagnostic agents
— V04C: Other diagnostic agents in atc
— V04CG: Gastric secretion test diagnostic agents
— V04CG03: Histamine phosphate
HCPCS
No data
Clinical
Clinical Trials
327 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypersensitivity | D006967 | EFO_0003785 | T78.40 | 3 | 18 | 1 | 3 | 19 | 43 |
| Allergic rhinitis | D065631 | — | J30.9 | 5 | 7 | 6 | 4 | 10 | 31 |
| Rhinitis | D012220 | EFO_0008521 | J31 | 3 | 7 | 5 | 4 | 11 | 29 |
| Pruritus | D011537 | — | L29 | 2 | 2 | — | 1 | 25 | 28 |
| Asthma | D001249 | EFO_0000270 | J45 | 2 | 5 | 2 | 4 | 11 | 23 |
| Allergic rhinitis seasonal | D006255 | EFO_0003956 | J30 | 1 | 6 | 1 | 1 | 4 | 13 |
| Healthy volunteers/patients | — | — | — | 6 | 1 | 1 | 1 | 4 | 12 |
| Urticaria | D014581 | EFO_0005531 | L50 | 2 | 3 | 1 | 3 | 3 | 11 |
| Multiple sclerosis | D009103 | EFO_0003885 | G35 | 1 | 3 | 4 | 1 | — | 9 |
| Allergic conjunctivitis | D003233 | EFO_0007141 | H10.44 | 1 | 3 | — | 2 | 2 | 8 |
Show 24 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 3 | 6 | 1 | — | 1 | 9 |
| Allergic rhinitis perennial | D012221 | EFO_1001417 | J30.89 | — | — | 5 | — | 2 | 7 |
| Disorders of excessive somnolence | D006970 | — | G47.1 | — | — | 6 | — | — | 6 |
| Sleepiness | D000077260 | — | R40.0 | — | — | 5 | — | — | 5 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | 4 | 5 |
| Pain | D010146 | EFO_0003843 | R52 | — | — | 1 | — | 4 | 5 |
| Lymphoma | D008223 | — | C85.9 | 1 | — | 2 | — | 1 | 4 |
| Relapsing-remitting multiple sclerosis | D020529 | EFO_0003929 | — | — | 1 | 2 | — | — | 3 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | 2 | — | 1 | 3 |
| Narcolepsy | D009290 | EFO_0000614 | G47.4 | — | 2 | 1 | — | — | 3 |
Show 29 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Atopic dermatitis | D003876 | EFO_0000274 | L20 | 1 | 2 | — | — | 5 | 8 |
| Dermatitis | D003872 | — | L30.9 | 1 | 2 | — | — | 5 | 8 |
| Syndrome | D013577 | — | — | — | 3 | — | — | 4 | 7 |
| Eczema | D004485 | — | L30.9 | — | 2 | — | — | 4 | 6 |
| Hepatitis b | D006509 | — | — | 1 | 4 | — | — | — | 5 |
| Chronic hepatitis b | D019694 | EFO_0004239 | B18.1 | 1 | 4 | — | — | — | 5 |
| Hepatitis | D006505 | — | K75.9 | 1 | 4 | — | — | — | 5 |
| Hepatitis a | D006506 | EFO_0007305 | B15 | 1 | 4 | — | — | — | 5 |
| Recurrence | D012008 | — | — | 1 | 4 | — | — | — | 4 |
| Food hypersensitivity | D005512 | EFO_1001890 | — | — | 1 | — | — | 3 | 4 |
Show 69 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hypertension | D006973 | EFO_0000537 | I10 | 1 | — | — | — | 2 | 3 |
| Colorectal neoplasms | D015179 | — | — | 2 | — | — | — | 1 | 3 |
| Motor activity | D009043 | EFO_0003940 | — | 1 | — | — | — | 1 | 2 |
| Cognitive dysfunction | D060825 | — | G31.84 | 2 | — | — | — | — | 2 |
| Chronic obstructive pulmonary disease | D029424 | EFO_0000341 | J44.9 | 1 | — | — | — | — | 1 |
| Familial primary pulmonary hypertension | D065627 | — | I27.0 | 1 | — | — | — | — | 1 |
| Urinary bladder neoplasms | D001749 | — | C67 | 1 | — | — | — | — | 1 |
| Carcinoma in situ | D002278 | — | D09.9 | 1 | — | — | — | — | 1 |
| Drug interactions | D004347 | — | — | 1 | — | — | — | — | 1 |
| Precursor cell lymphoblastic leukemia-lymphoma | D054198 | — | C91.0 | 1 | — | — | — | — | 1 |
Show 25 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Histamine release | D006636 | — | — | — | — | — | — | 10 | 10 |
| Angioedema | D000799 | EFO_0005532 | T78.3 | — | — | — | — | 3 | 3 |
| Exercise | D015444 | EFO_0000483 | — | — | — | — | — | 2 | 2 |
| Morphine dependence | D009021 | EFO_0005612 | — | — | — | — | — | 2 | 2 |
| Esophagitis | D004941 | HP_0100633 | K20 | — | — | — | — | 2 | 2 |
| Food intolerance | D000073923 | — | — | — | — | — | — | 2 | 2 |
| Bronchial hyperreactivity | D016535 | — | — | — | — | — | — | 2 | 2 |
| Sleep deprivation | D012892 | — | F51.12 | — | — | — | — | 2 | 2 |
| Bone nails | D001858 | — | — | — | — | — | — | 1 | 1 |
| Diarrhea | D003967 | — | R19.7 | — | — | — | — | 1 | 1 |
Show 66 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Histamine |
| INN | — |
| Description | Histamine is a member of the class of imidazoles that is 1H-imidazole substituted at position C-4 by a 2-aminoethyl group. It has a role as a human metabolite, a mouse metabolite and a neurotransmitter. It is an aralkylamino compound and a member of imidazoles. It is a conjugate base of a histaminium. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | NCCc1c[nH]cn1 |
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 12,266 documents
View more details
Safety
Black-box Warning
Black-box warning for: Positive skin test control - histamine
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
685 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use